OnKure Therapeutics (OKUR) Stock Price, News & Analysis

Company Overview

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research is centered on small-molecule therapies intended to target biological pathways that contribute to tumor growth and immune suppression.

OnKure’s lead investigational product is OKN4395, an orally administered EP2 receptor antagonist designed to help restore anti-tumor immune activity within the tumor microenvironment. The company has been evaluating OKN4395 in combination with pembrolizumab, an immune checkpoint inhibitor, for patients with advanced solid tumors. As an investigational therapy, OKN4395 has not been approved for commercial use.

Based in Boulder, Colorado, OnKure serves the oncology research and clinical-development market through its drug discovery and clinical programs. The company’s activities are primarily focused on advancing targeted cancer treatments through clinical development and potential regulatory approval.

Key Stats

• Today's Range: $2.02 to $2.26
• 50-Day Range: $2.10 to $4.21
• 52-Week Range: $2.01 to $5.38
• Volume: 501,451 shs
• Average Volume: 441,327 shs
• Market Capitalization: $90.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.50
• Consensus Rating: Hold

OnKure Therapeutics Stock Analysis - MarketRank™

OnKure Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 262nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

OnKure Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

OnKure Therapeutics has a consensus price target of $17.50, representing about 677.8% upside from its current price of $2.25.

Amount of Analyst Coverage

OnKure Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OnKure Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OnKure Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OnKure Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OnKure Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.10% of the float of OnKure Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

OnKure Therapeutics has a short interest ratio ("days to cover") of 4.76.

Change versus previous month

Short interest in OnKure Therapeutics has recently decreased by 11.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OnKure Therapeutics does not currently pay a dividend.

Dividend Growth

OnKure Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OnKure Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,155.00 in company stock.

Percentage Held by Insiders

2.17% of the stock of OnKure Therapeutics is held by insiders.

Percentage Held by Institutions

90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/20/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OKUR
• Previous Symbol: NASDAQ:OKUR
• CIK: 1637715
• Web: www.onkuretherapeutics.com
• Phone: (720) 307-2892
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OnKure Therapeutics: $17.50
• High Price Target: $21.00
• Low Price Target: $14.00
• Potential Upside/Downside: +677.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.01%
• Return on Assets: -45.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.75
• Quick Ratio: 26.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.11 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 40,400,000
• Free Float: 39,518,000
• Market Cap: $90.90 million
• Optionable: N/A
• Beta: 0.12